Cargando…

Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye

PURPOSE: In an earlier study we found normal adeno-associated viral vector type 2 (AAV2)-mediated GFP expression after intravitreal injection to one eye of normal C57BL/6J mice. However, GFP expression was very poor in the partner eye of the same mouse if this eye received an intravitreal injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wensheng, Kong, Fansheng, Li, Xia, Dai, Xufeng, Liu, Xiaoqiang, Zheng, Qinxiang, Wu, Ronghan, Zhou, Xiangtian, Lü, Fan, Chang, Bo, Li, Qiuhong, Hauswirth, William W., Qu, Jia, Pang, Ji-jing
Formato: Texto
Lenguaje:English
Publicado: Molecular Vision 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633462/
https://www.ncbi.nlm.nih.gov/pubmed/19190735
_version_ 1782164116968833024
author Li, Wensheng
Kong, Fansheng
Li, Xia
Dai, Xufeng
Liu, Xiaoqiang
Zheng, Qinxiang
Wu, Ronghan
Zhou, Xiangtian
Lü, Fan
Chang, Bo
Li, Qiuhong
Hauswirth, William W.
Qu, Jia
Pang, Ji-jing
author_facet Li, Wensheng
Kong, Fansheng
Li, Xia
Dai, Xufeng
Liu, Xiaoqiang
Zheng, Qinxiang
Wu, Ronghan
Zhou, Xiangtian
Lü, Fan
Chang, Bo
Li, Qiuhong
Hauswirth, William W.
Qu, Jia
Pang, Ji-jing
author_sort Li, Wensheng
collection PubMed
description PURPOSE: In an earlier study we found normal adeno-associated viral vector type 2 (AAV2)-mediated GFP expression after intravitreal injection to one eye of normal C57BL/6J mice. However, GFP expression was very poor in the partner eye of the same mouse if this eye received an intravitreal injection of the same vector one month after the initial intravitreal injection. We also found both injections worked well if they were subretinal. In this study, we tested whether the efficiency of subretinal AAV vector transduction is altered by a previous intravitreal injection in the partner eye and more importantly whether therapeutic efficiency is altered in the rd12 mouse (with a recessive RPE65 mutation) after the same injection series. METHODS: One μl of scAAV5-smCBA-GFP (1x10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old C57BL/6J mice and 1 μl of scAAV5-smCBA-hRPE65 (1x10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old rd12 mice Four weeks later, the same vectors were subretinally injected into the left eyes of the same C57BL/6J and rd12 mice. Left eyes of another cohort of eight-week-old rd12 mice received a single subretinal injection of the same scAAV5-smCBA-hRPE65 vector as the positive control. Dark-adapted electroretinograms (ERGs) were recorded five months after the subretinal injections. AAV-mediated GFP expression in C57BL/6J mice and RPE65 expression and ERG restoration in rd12 mice were evaluated five months after the second subretinal injection. Frozen section analysis was performed for GFP fluorescence in C57BL/6J mice and immunostaining for RPE65 in rd12 eyes. RESULTS: In rd12 mice, dark-adapted ERGs were minimal following the first intravitreal injection of scAAV5-smCBA-RPE65. Following subsequent subretinal injection in the partner eye, dramatic ERG restoration was recorded in that eye. In fact, ERG b-wave amplitudes were statistically similar to those from the eyes that received the initial subretinal injection at a similar age. In C57BL/6J mice, GFP positive cells were detected in eyes following the first intravitreal injection around the injection site. Strong GFP expression in both the retinal pigment epithelium (RPE) and photoreceptor (PR) cells was detected in the partner eyes following the subsequent subretinal injection. Immunostaining of retinal sections with anti-RPE65 antibody showed strong RPE65 expression mainly in the RPE cells of subretinally injected eyes but not in the intravitreally injected eyes except minimally around the injection site. CONCLUSIONS: These results show that an initial intravitreal injection of AAV vectors to one eye of a mouse does not influence AAV-mediated gene expression or related therapeutic effects in the other eye when vectors are administered to the subretinal space. This suggests that the subretinal space possesses a unique immune privilege relative to the vitreous cavity.
format Text
id pubmed-2633462
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-26334622009-02-02 Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye Li, Wensheng Kong, Fansheng Li, Xia Dai, Xufeng Liu, Xiaoqiang Zheng, Qinxiang Wu, Ronghan Zhou, Xiangtian Lü, Fan Chang, Bo Li, Qiuhong Hauswirth, William W. Qu, Jia Pang, Ji-jing Mol Vis Research Article PURPOSE: In an earlier study we found normal adeno-associated viral vector type 2 (AAV2)-mediated GFP expression after intravitreal injection to one eye of normal C57BL/6J mice. However, GFP expression was very poor in the partner eye of the same mouse if this eye received an intravitreal injection of the same vector one month after the initial intravitreal injection. We also found both injections worked well if they were subretinal. In this study, we tested whether the efficiency of subretinal AAV vector transduction is altered by a previous intravitreal injection in the partner eye and more importantly whether therapeutic efficiency is altered in the rd12 mouse (with a recessive RPE65 mutation) after the same injection series. METHODS: One μl of scAAV5-smCBA-GFP (1x10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old C57BL/6J mice and 1 μl of scAAV5-smCBA-hRPE65 (1x10(13) genome containing viral particles per ml) was intravitreally injected into the right eyes of four-week-old rd12 mice Four weeks later, the same vectors were subretinally injected into the left eyes of the same C57BL/6J and rd12 mice. Left eyes of another cohort of eight-week-old rd12 mice received a single subretinal injection of the same scAAV5-smCBA-hRPE65 vector as the positive control. Dark-adapted electroretinograms (ERGs) were recorded five months after the subretinal injections. AAV-mediated GFP expression in C57BL/6J mice and RPE65 expression and ERG restoration in rd12 mice were evaluated five months after the second subretinal injection. Frozen section analysis was performed for GFP fluorescence in C57BL/6J mice and immunostaining for RPE65 in rd12 eyes. RESULTS: In rd12 mice, dark-adapted ERGs were minimal following the first intravitreal injection of scAAV5-smCBA-RPE65. Following subsequent subretinal injection in the partner eye, dramatic ERG restoration was recorded in that eye. In fact, ERG b-wave amplitudes were statistically similar to those from the eyes that received the initial subretinal injection at a similar age. In C57BL/6J mice, GFP positive cells were detected in eyes following the first intravitreal injection around the injection site. Strong GFP expression in both the retinal pigment epithelium (RPE) and photoreceptor (PR) cells was detected in the partner eyes following the subsequent subretinal injection. Immunostaining of retinal sections with anti-RPE65 antibody showed strong RPE65 expression mainly in the RPE cells of subretinally injected eyes but not in the intravitreally injected eyes except minimally around the injection site. CONCLUSIONS: These results show that an initial intravitreal injection of AAV vectors to one eye of a mouse does not influence AAV-mediated gene expression or related therapeutic effects in the other eye when vectors are administered to the subretinal space. This suggests that the subretinal space possesses a unique immune privilege relative to the vitreous cavity. Molecular Vision 2009-02-06 /pmc/articles/PMC2633462/ /pubmed/19190735 Text en http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Wensheng
Kong, Fansheng
Li, Xia
Dai, Xufeng
Liu, Xiaoqiang
Zheng, Qinxiang
Wu, Ronghan
Zhou, Xiangtian
Lü, Fan
Chang, Bo
Li, Qiuhong
Hauswirth, William W.
Qu, Jia
Pang, Ji-jing
Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title_full Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title_fullStr Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title_full_unstemmed Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title_short Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
title_sort gene therapy following subretinal aav5 vector delivery is not affected by a previous intravitreal aav5 vector administration in the partner eye
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633462/
https://www.ncbi.nlm.nih.gov/pubmed/19190735
work_keys_str_mv AT liwensheng genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT kongfansheng genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT lixia genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT daixufeng genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT liuxiaoqiang genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT zhengqinxiang genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT wuronghan genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT zhouxiangtian genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT lufan genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT changbo genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT liqiuhong genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT hauswirthwilliamw genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT qujia genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye
AT pangjijing genetherapyfollowingsubretinalaav5vectordeliveryisnotaffectedbyapreviousintravitrealaav5vectoradministrationinthepartnereye